Medincell shares fell sharply on the back of full-year 2026 financials that missed investor expectations and introduced new timeline risk. The stock declined 14.1% to trade at 24.08 after the French biopharmaceutical firm disclosed several negative developments in its results.
Key financials released for FY2026 showed total income of 24.3 million, down from 27.7 million in the prior year. UZEDY royalties, however, rose 42% to reach 9.3 million.
Most notably, Medincell recorded an operating loss of 20.8 million, a marked increase from an operating loss of 10.8 million a year earlier. Management attributed the deterioration in operating results to an acceleration of investment in research and development and in commercial development activities.
Investor sentiment was further affected when the company revealed that a clinical program run in partnership with AbbVie has been delayed into 2027, removing what had been anticipated as an upcoming catalyst for the shares.
There were some supportive elements in the report. Teva's net sales of UZEDY were reported at $215 million for FY2026, an increase of 52.5% from $141 million the year before. Company management highlighted UZEDY as the fastest-growing long-acting injectable in its category.
Nonetheless, the financial results included a notable non-cash headwind: a 5.4 million accounting revaluation related to warrants granted to the European Investment Bank. That revaluation was linked to the rise in Medincell's share price and reduced headline income.
Trading activity underscored the market response. Volume surged to about 256,720 shares on the day of the announcement, up from roughly 111,240 shares in the prior session.
Broader market conditions offered little comfort. The CAC 40 index did not provide a meaningful tailwind, and French financial coverage noted that the European Central Bank raised key rates for the first time in three years - a move the Governor of the Banque de France described as unlikely to spark a sustained upward market cycle.
Taken together, the package of a near-doubling net loss, a decline in headline income driven by absent milestone payments, a steep increase in operating expenses and the AbbVie trial delay proved too much for investors to absorb. This reaction occurred despite the firms strengthened UZEDY royalty momentum and a cash balance that management described as approximately 85 million, which they say provides long-term financial visibility.
The stock had previously rebounded from a 52-week low of 15.39 but surrendered a substantial portion of those gains as the market re-priced execution and timeline risk.
What investors saw
- Wider net and operating losses for FY2026.
- Higher UZEDY royalties offset by lower overall income compared with the prior year.
- Delay of an AbbVie-partnered clinical program into 2027, eliminating an expected near-term catalyst.